jueves, 12 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 10, 2026

Wells Fargo Q1 Earnings on the Deck: What's in Store for the Stock?

View original at finance.yahoo.com
Wells Fargo Q1 Earnings on the Deck: What's in Store for the Stock? Wells Fargo & Company WFC is slated to report first-quarter 2026 earnings results on April 14, 2026, before market open…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Net interest income expected to be $12.3 billion in Q1 2026, indicating 6.9% rise from year-ago quarter

    60% confidence

  • Investment advisory and other asset-based fee revenues expected to be $2.9 billion in Q1 2026, indicating 12.8% year-over-year rise

    60% confidence

  • Wells Fargo Q1 2026 earnings per share expected to be $1.57, representing 23.6% improvement from prior-year quarter

    60% confidence

  • Wells Fargo has outpaced earnings consensus estimates in the trailing four quarters with average surprise of 7.53%

    60% confidence

  • Wells Fargo Q1 2026 revenues expected to reach $21.73 billion, representing 7.8% year-over-year growth

    60% confidence

  • Demand for commercial and industrial and consumer loans was impressive in the first two months of Q1 2026, while real estate loan demand was subdued

    60% confidence

  • Mortgage banking revenues expected to be $283 million in Q1 2026, suggesting 14.8% decline from year-ago level

    60% confidence

Data points we hold from this source

Wells Fargo & Company · mortgage banking revenues283 USD
Wells Fargo & Company · investment advisory fee growth12.8 percent
Wells Fargo & Company · net interest income growth6.9 percent
Wells Fargo & Company · investment advisory fees2.9 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,565 documentos fuente archivados
Consulta estos datos → isubstrate.com
Wells Fargo Q1 Earnings on the Deck: What's in Store for the Stock? — Source | Via News | es.VIA.NEWS